Michael A. Tonelli michael.tonelli.wg11@wharton.upenn.edu


Tufts University, Medford, MA B.A., Magna Cum Laude, Economics, International Relations and Spanish, 2004


C. Renee Vaughn


renee.vaughn.wg11@wharton.upenn.edu Duke University, Chapel Hill, NC A.B., Public Policy, 2005


John Voith


john.voith.wg11@wharton.upenn.edu Harvard College, Cambridge, MA A.B., Biology and Public Policy, 2007 Harvard Kennedy School of Government, Cambridge, MA M.P.A. Candidate, 2012


An opportunity at a consulting firm to work with companies in the health care provider/services space.


Deloitte Consulting, LLP, Boston, MA Summer Associate, Strategy & Operations, Summer 2010


Assessed the impact of health reform legislation on an integrated delivery health system in the Midwest; primarily focused on implications for quality improvement and strategic opportunities given current market and competitor positioning.


Merrill Lynch & Co., New York, NY Associate, Healthcare Public Finance Group, 2007-2009


Structured capital market solutions, including debt originations, derivative strategies, and divesture and acquisi- tion opportunities for hospitals and health systems throughout the United States. Facilitated smooth deal process through coordinating transaction teams; developing pitch, board and rating agency presentations; reviewing offering documents; and liaising with derivative, operations, underwriting, sales, and trading desks. Managed and executed $2.9B of bond issuances and $1.5B of derivative products.


Commerce Capital Markets, Inc., New York, NY


Associate Analyst, Public Finance Group, 2004-2007


Performed quantitative analysis and transactional support functions, specializing in debt origination for mid-market health care, higher education and human service agencies in New York, New Jersey and Pennsylvania.


An opportunity in the health care sector with a focus on strategy.


Abbott Laboratories, Abbott Park, IL Summer Associate, Summer 2010 Led and developed a strategic assess- ment methodology for use on more than 6000 drugs; Performed a thor- ough review of 15 drug opportunities ranging in potential value from $800M to $2B and presented to senior management.


The White House, Washington, DC Summer Intern, Summer 2009 Facilitated and organized seven public interest meetings between 20 stakeholders and White House Office of Health Reform Chief Nancy-Ann DeParle and HHS secretary Kathleen Sebelius.


Duke Hospital, Durham, NC Analyst, 2007-2009


Managed and supervised 3 disease site teams in Oncology clinic with three direct and 20 indirect reports. Performed cost analysis on impact of inadequate physician scheduling which revealed $60K in annual lost revenue. Led launch of new clinic, designing space, modeling expected revenue, and monitoring room utilization.


Triage Consulting Group, Atlanta, GA Senior Associate, 2005-2009


Managed a team of four associates to identify $1.6M in underpaid dollars and recovered $1M of that amount within five months. Performed finan- cial reporting and reimbursement analysis for eight major hospital organizations, recovering more than $6M.


An opportunity within an entrepreneur- ial team in the health IT or health services industry.


Athenahealth, Watertown, MA MBA Intern, Summer and Fall 2010 Developed a 5 year strategic opera- tions plan to save more than $10M and improve service quality across service divisions. Also, developed presentations on government meaningful use incentive program, empowering more than 100 internal account managers to teach clients how to qualify for $44,000/year.


IMS Health Strategy Consulting Division, New York, NY Consultant, 2009 Analyst, 2007-2008


Managed pharmaceutical company clients as well as internal teams, each project worth more than $150,000 (billing revenue). Also, developed detailed business proposals in response to RFPs, leading to engagements worth total of $400,000 (50% win rate). Project examples: 1) Developed pricing strategy for an undifferentiated diabetes drug through conjoint analysis of price sensitivity of payers and providers. Demonstrated 5% pricing premium potential, resulting in adoption of suggested strategy and 2) advised company seeking to re-enter the vac- cine business after 30-year absence. Created corporate policy document, leading to multiple successful acquisitions.


28


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40